

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Gaush Meditech Ltd

高視医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2407)

VOLUNTARY ANNOUNCEMENT FREQUENCY-DOMAIN BIOMETER OBTAINED MEDICAL DEVICE REGISTRATION CERTIFICATE IN CHINA

This announcement is made by Gaush Meditech Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis, to inform the shareholders and potential investors of the Company regarding the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that Gaush Neotech Ltd* (高視創新科技有限公司) (“**Gaush Neotech**”), a subsidiary of the Company, has recently obtained the medical device registration certificate for its “frequency-domain biometer” from the Jiangsu Medical Products Administration.

According to the White Paper of China Eye Health released by the National Health Commission in 2023, the overall myopia rate among Chinese adolescents was approximately 53.6%. With the continuous expansion of the myopic population, the market demand for myopia prevention and control has also grown rapidly. According to the White Paper of China Optical Lenses Industry Research released by Frost & Sullivan, China’s myopia prevention and control market has continued to expand in recent years. Following an acceleration starting in 2022, the market size reached RMB14.68 billion in 2023, representing a year-on-year increase of 43.2%. Biometers, which are essential devices for myopia prevention and control, enable micron-level precision measurements of ocular parameters such as axial length, corneal curvature and lens thickness, thereby playing a critical role in monitoring myopia progression in adolescents and evaluating the efficacy of myopia control interventions. In addition, biometers are indispensable equipment for the preoperative assessment of refractive surgery candidates.

The frequency-domain biometer (Registration Certificate No.: Su Xie Zhu Zhun 20252161508) of Gaush Neotech approved this time was developed based on a new-generation frequency-domain measurement principle, which, compared with most traditional biometers that adopt time-domain measurement principles, offers higher resolution, faster imaging speed and an improved signal-to-noise ratio. The biometer also incorporates an innovative dual-optical-path design (Patent No.: CN118526152A), which enables real-time tomographic imaging of the cornea, retina and choroid during ocular parameter measurement, thereby supporting myopia follow-up and assisting physicians in screening for myopia-related complications. The biometer was independently developed by Gaush Neotech over a period of two years and has now achieved 100% domestic production of key optical, mechanical and electronic components.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board

Gaush Meditech Ltd

Mr. Gao Tieta

Chairman and Executive Director

Hong Kong, August 4, 2025

As of the date of this announcement, the Board comprises Mr. Gao Tieta as Chairman and executive Director, Mr. Liu Xinwei, Mr. Zhao Xinli, Mr. Zhang Jianjun and Ms. Li Wenqi as executive Directors, Dr. David Guowei Wang as non-executive Director, and Mr. Feng Xin, Mr. Wang Li-Shin and Mr. Chan Fan Shing as independent non-executive Directors.